• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    France Pharmacovigilance Market

    ID: MRFR/Pharma/49693-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    France Pharmacovigilance Market Research Report By Service Type (Adverse Event Reporting, Risk Assessment, Data Mining, Pharmacovigilance Consulting), By Deployment Mode (Cloud-Based, On-Premise), By Source (Spontaneous Reporting, Literature Reports, Scheduled Reporting) and By End-user (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations)-Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    France Pharmacovigilance Market Research Report-Forecast to 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    France Pharmacovigilance Market Summary

    The France Pharmacovigilance market is projected to grow significantly over the next decade.

    Key Market Trends & Highlights

    France Pharmacovigilance Key Trends and Highlights

    • The market valuation is expected to increase from 296.2 USD Million in 2024 to 664.5 USD Million by 2035.
    • A compound annual growth rate (CAGR) of 7.62 percent is anticipated from 2025 to 2035.
    • This growth trajectory indicates a robust demand for pharmacovigilance services in France.
    • Growing adoption of advanced data analytics due to the need for enhanced drug safety monitoring is a major market driver.

    Market Size & Forecast

    2024 Market Size 296.2 (USD Million)
    2035 Market Size 664.5 (USD Million)
    CAGR (2025-2035) 7.62%

    Major Players

    Teva Pharmaceuticals, Pfizer, Boehringer Ingelheim, Amgen, Merck & Co, AstraZeneca, Roche, GlaxoSmithKline, Takeda, Eli Lilly, Johnson & Johnson, AbbVie, Sanofi, Novartis, Bristol Myers Squibb

    France Pharmacovigilance Market Trends

    The market for pharmacovigilance in France is driven by a number of important factors, chief among them being the stricter regulations and the growing emphasis on patient safety. The French government stresses the significance of keeping an eye on pharmaceutical safety through its regulating body, ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé).

    Pharmaceutical companies have adopted more sophisticated pharmacovigilance procedures as a result of this dedication. Furthermore, the development of electronic reporting systems and digital health technologies is making it possible to gather and analyse adverse drug reactions more effectively, which improves pharmacovigilance initiatives overall.

    There are several opportunities in the French pharmacovigilance market, especially when it comes to using machine learning and artificial intelligence to enhance data analysis and signal detection. Businesses can improve their ability to handle massive amounts of data more efficiently by utilising these technologies.

    Additionally, partnerships between regulatory bodies and pharmaceutical companies may result in better safety evaluation techniques, opening up new opportunities in the market. Real-world evidence and patient-centric approaches are becoming increasingly important in pharmacovigilance, according to recent developments.

    The value of collecting data from real patient experiences is becoming more widely acknowledged in the French healthcare system. This data can offer important insights into pharmaceutical safety outside of clinical trials.

    The trajectory of pharmacovigilance efforts in France is being shaped by this move towards a more comprehensive understanding of patient outcomes. Transparency and open communication with patients and healthcare providers are also increasingly being emphasised.

    France is positioned for developments that can improve public health outcomes if stakeholders collaborate to strengthen pharmacovigilance frameworks.

    France Pharmacovigilance Market Drivers

    Market Segment Insights

    Get more detailed insights about France Pharmacovigilance Market Research Report-Forecast to 2035

    Regional Insights

    Key Players and Competitive Insights

    The France Pharmacovigilance Market is characterized by its dynamic landscape, driven by increasing regulatory requirements and a growing emphasis on patient safety.

    As the pharmaceutical industry in France continues to evolve, stakeholders are increasingly focused on implementing robust pharmacovigilance systems to monitor drug safety and ensure compliance with both national and European Union regulations.

    This has led to a competitive environment where pharmaceutical companies, biopharmaceutical firms, and service providers aim to enhance their pharmacovigilance capabilities and offerings. The market's growth is further propelled by advancements in technology and data analytics, allowing companies to more efficiently assess and manage the risks associated with drug use.

    As new therapies are launched and existing drugs are monitored, the competition intensifies, necessitating that companies invest in their pharmacovigilance frameworks to maintain compliance and safeguard public health.

    Teva Pharmaceuticals has established a significant presence within the France Pharmacovigilance Market, leveraging its extensive portfolio and expertise in generic and specialty medications. The company is recognized for its commitment to maintaining high standards of drug safety and efficacy, which is vital in a market increasingly focused on regulatory compliance.

    Teva's strengths lie in its strong research and development framework and its ability to rapidly adapt to changing regulations, making it a formidable player in the French market.

    Furthermore, the company effectively collaborates with regulatory bodies and healthcare professionals to facilitate effective monitoring of adverse drug reactions. This approach not only strengthens Teva's standing within the industry but also builds trust among healthcare providers and patients alike, thereby reinforcing its market position.

    Pfizer, as a global leader in the pharmaceutical industry, also has a well-established foothold in the France Pharmacovigilance Market. The company is known for its diverse portfolio of key products and services, including vaccines, oncology medications, and advanced therapeutics which necessitate comprehensive safety monitoring.

    Pfizer’s strengths include a robust pharmacovigilance infrastructure combined with a proactive approach towards regulatory compliance and risk management. The company's initiatives often incorporate advanced technologies to enhance data collection and analysis, ensuring timely reporting of adverse events, which is essential for maintaining drug safety.

    Additionally, Pfizer has pursued strategic mergers and acquisitions that have expanded its therapeutic offerings and strengthened its market position, allowing it to better serve the French healthcare ecosystem.

    Through these strategic moves, Pfizer remains a key player in pharmacovigilance, aligning its operations with the unique regulatory landscape of France and reinforcing its commitment to patient safety.

    Key Companies in the France Pharmacovigilance Market market include

    Industry Developments

    In recent months, the France Pharmacovigilance Market has witnessed significant developments. Notably, Teva Pharmaceuticals has expanded its safety monitoring division, enhancing its capabilities to track adverse drug reactions, while Pfizer has implemented advanced data analytics to bolster its pharmacovigilance processes.

    In terms of market activity, Boehringer Ingelheim announced a strategic acquisition of a local biotech firm in September 2023 to strengthen its regional presence in drug safety and efficacy, reflecting a growing trend among major players like Merck and Co and AstraZeneca who are also focusing on technological advancements in pharmacovigilance.

    Sanofi has emphasized its commitment to regulatory compliance by increasing transparency in reporting adverse events, aligning with new European directives. Meanwhile, Roche and Amgen have engaged in collaborative efforts to enhance their pharmacovigilance systems through shared data platforms, contributing to improved patient safety outcomes.

    Over the last two to three years, France’s regulatory landscape has evolved with the implementation of stricter guidelines and a stronger emphasis on real-world evidence, which has led to increased market validation and growth potential for major pharmaceutical companies including Johnson and Johnson, AbbVie, and Novartis in their safety monitoring practices.

    Market Segmentation

    Outlook

    • Pharmaceutical Companies
    • Biotechnology Companies
    • Contract Research Organizations

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 279.38(USD Million)
    MARKET SIZE 2024 296.25(USD Million)
    MARKET SIZE 2035 664.5(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 7.62% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Teva Pharmaceuticals, Pfizer, Boehringer Ingelheim, Amgen, Merck & Co, AstraZeneca, Roche, GlaxoSmithKline, Takeda, Eli Lilly, Johnson & Johnson, AbbVie, Sanofi, Novartis, Bristol Myers Squibb
    SEGMENTS COVERED Service Type, Deployment Mode, Source, End User
    KEY MARKET OPPORTUNITIES Increased regulatory compliance demands, Rising adoption of digital solutions, Growth in adverse event reporting, Expansion of biopharmaceutical sector, Enhanced focus on patient safety
    KEY MARKET DYNAMICS Regulatory compliance requirements, Increasing adverse event reporting, Growth in biopharmaceuticals, Advanced data analytics adoption, Rising patient safety concerns
    COUNTRIES COVERED France

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the current market size of the France Pharmacovigilance Market for the year 2024?

    The France Pharmacovigilance Market is expected to be valued at 296.25 million USD in 2024.

    What is the projected market size of the France Pharmacovigilance Market by 2035?

    By 2035, the France Pharmacovigilance Market is anticipated to reach a valuation of 664.5 million USD.

    What is the expected compound annual growth rate (CAGR) for the France Pharmacovigilance Market from 2025 to 2035?

    The expected CAGR for the France Pharmacovigilance Market from 2025 to 2035 is 7.62%.

    Which segment of the France Pharmacovigilance Market is expected to dominate in terms of revenue?

    The Adverse Event Reporting segment is expected to dominate the France Pharmacovigilance Market, valued at 100 million USD in 2024.

    What will be the market value of Risk Assessment services in the France Pharmacovigilance Market by 2035?

    The market value for Risk Assessment services in the France Pharmacovigilance Market is expected to be 160 million USD by 2035.

    Who are the major players in the France Pharmacovigilance Market?

    Major players in the France Pharmacovigilance Market include Teva Pharmaceuticals, Pfizer, Boehringer Ingelheim, and Merck & Co.

    What is the anticipated market value for Data Mining services in 2035?

    The Data Mining services segment is projected to reach 138 million USD in the France Pharmacovigilance Market by 2035.

    What challenges does the France Pharmacovigilance Market currently face?

    Challenges in the France Pharmacovigilance Market include regulatory compliance and managing large volumes of data.

    What opportunities exist in the France Pharmacovigilance Market?

    Opportunities in the France Pharmacovigilance Market include advancements in data analytics and the increasing focus on patient safety.

    What will be the market value for Pharmacovigilance Consulting services in 2035?

    Pharmacovigilance Consulting services are expected to reach a market value of 138.5 million USD by 2035 in France.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. France Pharmacovigilance Market, BY Service Type (USD Million)
    45. Adverse Event Reporting
    46. Risk Assessment
    47. Data Mining
    48. Pharmacovigilance Consulting
    49. France Pharmacovigilance Market, BY Deployment Mode (USD Million)
    50. Cloud-Based
    51. On-Premise
    52. France Pharmacovigilance Market, BY Source (USD Million)
    53. Spontaneous Reporting
    54. Literature Reports
    55. Scheduled Reporting
    56. France Pharmacovigilance Market, BY End User (USD Million)
    57. Pharmaceutical Companies
    58. Biotechnology Companies
    59. Contract Research Organizations
    60. Competitive Landscape
    61. Overview
    62. Competitive Analysis
    63. Market share Analysis
    64. Major Growth Strategy in the Pharmacovigilance Market
    65. Competitive Benchmarking
    66. Leading Players in Terms of Number of Developments in the Pharmacovigilance Market
    67. Key developments and growth strategies
    68. New Product Launch/Service Deployment
    69. Merger & Acquisitions
    70. Joint Ventures
    71. Major Players Financial Matrix
    72. Sales and Operating Income
    73. Major Players R&D Expenditure. 2023
    74. Company Profiles
    75. Teva Pharmaceuticals
    76. Financial Overview
    77. Products Offered
    78. Key Developments
    79. SWOT Analysis
    80. Key Strategies
    81. Pfizer
    82. Financial Overview
    83. Products Offered
    84. Key Developments
    85. SWOT Analysis
    86. Key Strategies
    87. Boehringer Ingelheim
    88. Financial Overview
    89. Products Offered
    90. Key Developments
    91. SWOT Analysis
    92. Key Strategies
    93. Amgen
    94. Financial Overview
    95. Products Offered
    96. Key Developments
    97. SWOT Analysis
    98. Key Strategies
    99. Merck & Co
    100. Financial Overview
    101. Products Offered
    102. Key Developments
    103. SWOT Analysis
    104. Key Strategies
    105. AstraZeneca
    106. Financial Overview
    107. Products Offered
    108. Key Developments
    109. SWOT Analysis
    110. Key Strategies
    111. Roche
    112. Financial Overview
    113. Products Offered
    114. Key Developments
    115. SWOT Analysis
    116. Key Strategies
    117. GlaxoSmithKline
    118. Financial Overview
    119. Products Offered
    120. Key Developments
    121. SWOT Analysis
    122. Key Strategies
    123. Takeda
    124. Financial Overview
    125. Products Offered
    126. Key Developments
    127. SWOT Analysis
    128. Key Strategies
    129. Eli Lilly
    130. Financial Overview
    131. Products Offered
    132. Key Developments
    133. SWOT Analysis
    134. Key Strategies
    135. Johnson & Johnson
    136. Financial Overview
    137. Products Offered
    138. Key Developments
    139. SWOT Analysis
    140. Key Strategies
    141. AbbVie
    142. Financial Overview
    143. Products Offered
    144. Key Developments
    145. SWOT Analysis
    146. Key Strategies
    147. Sanofi
    148. Financial Overview
    149. Products Offered
    150. Key Developments
    151. SWOT Analysis
    152. Key Strategies
    153. Novartis
    154. Financial Overview
    155. Products Offered
    156. Key Developments
    157. SWOT Analysis
    158. Key Strategies
    159. Bristol Myers Squibb
    160. Financial Overview
    161. Products Offered
    162. Key Developments
    163. SWOT Analysis
    164. Key Strategies
    165. References
    166. Related Reports
    167. France Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY SERVICE TYPE, 2019-2035 (USD Billions)
    168. France Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY DEPLOYMENT MODE, 2019-2035 (USD Billions)
    169. France Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY SOURCE, 2019-2035 (USD Billions)
    170. France Pharmacovigilance Market SIZE ESTIMATES & FORECAST, BY END USER, 2019-2035 (USD Billions)
    171. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    172. ACQUISITION/PARTNERSHIP
    173. MARKET SYNOPSIS
    174. FRANCE PHARMACOVIGILANCE MARKET ANALYSIS BY SERVICE TYPE
    175. FRANCE PHARMACOVIGILANCE MARKET ANALYSIS BY DEPLOYMENT MODE
    176. FRANCE PHARMACOVIGILANCE MARKET ANALYSIS BY SOURCE
    177. FRANCE PHARMACOVIGILANCE MARKET ANALYSIS BY END USER
    178. KEY BUYING CRITERIA OF PHARMACOVIGILANCE MARKET
    179. RESEARCH PROCESS OF MRFR
    180. DRO ANALYSIS OF PHARMACOVIGILANCE MARKET
    181. DRIVERS IMPACT ANALYSIS: PHARMACOVIGILANCE MARKET
    182. RESTRAINTS IMPACT ANALYSIS: PHARMACOVIGILANCE MARKET
    183. SUPPLY / VALUE CHAIN: PHARMACOVIGILANCE MARKET
    184. PHARMACOVIGILANCE MARKET, BY SERVICE TYPE, 2025 (% SHARE)
    185. PHARMACOVIGILANCE MARKET, BY SERVICE TYPE, 2019 TO 2035 (USD Billions)
    186. PHARMACOVIGILANCE MARKET, BY DEPLOYMENT MODE, 2025 (% SHARE)
    187. PHARMACOVIGILANCE MARKET, BY DEPLOYMENT MODE, 2019 TO 2035 (USD Billions)
    188. PHARMACOVIGILANCE MARKET, BY SOURCE, 2025 (% SHARE)
    189. PHARMACOVIGILANCE MARKET, BY SOURCE, 2019 TO 2035 (USD Billions)
    190. PHARMACOVIGILANCE MARKET, BY END USER, 2025 (% SHARE)
    191. PHARMACOVIGILANCE MARKET, BY END USER, 2019 TO 2035 (USD Billions)
    192. BENCHMARKING OF MAJOR COMPETITORS

    France Pharmacovigilance Market Segmentation

    • Pharmacovigilance Market By Service Type (USD Million, 2019-2035)

      • Adverse Event Reporting
      • Risk Assessment
      • Data Mining
      • Pharmacovigilance Consulting

     

    • Pharmacovigilance Market By Deployment Mode (USD Million, 2019-2035)

      • Cloud-Based
      • On-Premise

     

    • Pharmacovigilance Market By Source (USD Million, 2019-2035)

      • Spontaneous Reporting
      • Literature Reports
      • Scheduled Reporting

     

    • Pharmacovigilance Market By End User (USD Million, 2019-2035)

      • Pharmaceutical Companies
      • Biotechnology Companies
      • Contract Research Organizations
    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials